Study identification

EU PAS number

EUPAS1000000866

Study ID

1000000866

Official title and acronym

Estudio de utilización de medicamentos para el tratamiento de la insuficiencia cardíaca (IDIAP-IC-2025) / Drug utilization study of treatments for heart failure (IDIAP-IC-2025)

DARWIN EU® study

No

Study countries

Spain

Study description

Heart failure (HF) is usually classified according to left ventricular ejection fraction (LVEF), distinguishing between three phenotypes: HF with reduced LVEF (HFrEF), when it is ≤ 40%, HF with mildly reduced or intermediate LVEF (HFmrEF), when it is between 41-49%, and HF with preserved LVEF (HFpEF), if LVEF ≥ 50%. It is also common to use the New York Heart Association (NYHA) functional classification to describe the degree of HF, based on the severity of the patient's symptoms. The goal of HF treatment is to reduce mortality, reduce the risk of hospitalizations due to disease decompensation, and improve symptoms. The recommended pharmacological treatment based on scientific evidence varies depending on the HF phenotype. The objective of this study is to describe the clinical and sociodemographic characteristics of people diagnosed with HF and the pharmacological treatments used to manage the disease. We recently conducted this study in Catalonia using the regional SIDIAP database. Our goal is to replicate the same study with national data from BIFAP in order to compare the results.

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

Maria Giner-Soriano 0000-0003-3750-9233

Primary lead investigator
ORCID number:
0000-0003-3750-9233

Study timelines

Date when funding contract was signed

Planned:

Study start date

Planned:
Actual:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
No external funding
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable